Cogentus Enrolls First European Patient in Phase III Study of Combination Drug
Posted on: Monday, 16 June 2008, 09:01 CDT
Cogentus Pharmaceuticals has enrolled the first patient in Europe in the company's pivotal Phase III study of its novel combination medicine CGT-2168. The patient entered the Cogent-1 study at the Zadebie cardiology clinic in Skierniewice, Poland.
The study, which began in North America in January, 2008 is evaluating the antiplatelet medicine CGT-2168, a combination of clopidogrel (currently marketed by Bristol-Myers Squibb and Sanofi-Aventis as Plavix) and a gastroprotectant (omeprazole) in a single pill.
Developed by Cogentus, CGT-2168 is designed to provide cardiovascular benefits while reducing potentially serious gastrointestinal side effects commonly associated with dual antiplatelet therapy.
Mark Goldsmith, Cogentus chairman and CEO, said: "Cogent has been very well received by the medical community in North America, with strong enrollment. Now we will begin to gather important data from investigators in Europe and broaden the patient base of the study."
Source: Datamonitor
Related Articles
- Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer
- Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections
- Wyeth and Progenics Initiate New Clinical Studies to Investigate Additional Patient Populations for Methylnaltrexone
- Results of PEG-INTRON(R) and REBETOL(R) Study in Retreating Hepatitis C Patients Who Failed Previous Combination Therapy Presented at AASLD
- Allos Therapeutics Initiates Pivotal Phase 2 Study of PDX in Patients With Peripheral T-Cell Lymphoma
- New Study: Despite Suicidality Risks, Patients on Antidepressants Have Received Far Less Follow-Up Care Than is Currently Recommended
- PTC Therapeutics Initiates Second Phase 2 Study of PTC124 in Patients With Cystic Fibrosis in Israel
- Clinically Significant Incidental Findings on the Unenhanced CT Portion of PET/CT Studies: Frequency in 250 Patients
- Study of Breast Cancer Patients Showed Regimen Including EMEND-R- -Aprepitant- Prevented Nausea and Vomiting After Chemotherapy in More Patients Than a Standard Regimen
- Nabi Biopharmaceuticals Announces Initiation of New StaphVAX(R) Immunogenicity Study in Orthopedic Surgery Patients
 |
 |
User Comments (0)
RSS Feeds